UpFrontPSMA: 177Lu-PSMA-617 shows potential in mHSPC
In the experimental arm, 41% of patients had an undetectable PSA level at week 48 vs 16% in the control arm (OR=3.88; 95% CI, 1.61-9.38, P = .002).
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
EV/pembrolizumab yields PFS, OS, ORR benefits regardless of Nectin-4 level
“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
Serum glycoproteins may predict response to nivolumab/cabozantinib in aRCC
On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01).
Radium223, chemotherapy improves mCRPC quality of life in phase 2 RAPSON
New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.
